|Bid||3.3600 x 800|
|Ask||3.6000 x 1800|
|Day's Range||3.1200 - 3.5000|
|52 Week Range||0.5200 - 5.4300|
|Beta (5Y Monthly)||0.74|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) * Aileron Therapeutics Inc (NASDAQ: ALRN) * Anchiano Therapeutics Ltd - ADR (NASDAQ: ANCN) * Athira Pharma Inc (NASDAQ: ATHA) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) * Blueprint Medicines Corp (NASDAQ: BPMC) * Cleveland BioLabs, Inc. (NASDAQ: CBLI)(announced a reverse merger with Cytocom) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Immunomedics, Inc. (NASDAQ: IMMU) * Insmed Incorporated (NASDAQ: INSM) * Laboratory Corp. of America Holdings (NYSE: LH) * Pacific Biosciences of California Inc (NASDAQ: PACB) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Alector Inc (NASDAQ: ALEC) * Aligos Therapeutics Inc (NASDAQ: ALGS) * Avenue Therapeutics Inc (NASDAQ: ATXI) * Baudax Bio Inc (NASDAQ: BXRX) (issued a corporate update) * Codiak BioSciences Inc (NASDAQ: CDAK) (listed on Nasdaq on Oct. 14) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * FSD Pharma Inc (NASDAQ: HUGE) * Gilead Sciences, Inc. (NASDAQ: GILD) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * ProQR Therapeutics NV (NASDAQ: PRQR) * Titan Pharmaceuticals, Inc (NASDAQ: TTNP)Stocks In Focus Prothena to Advance Parkinson's Disease Drug Into Large-scale Confirmatory Study Prothena Corporation PLC (NASDAQ: PRTA) said, based on positive signals of efficacy consistent with disease modification in the PASADENA study, it along with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) plans to advance prasinezumab into a Phase 2b study in patients with early Parkinson's disease. The study is likely to be initiated in 2021, it added.The study will further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA to include patients with early Parkinson's disease on stable levodopa therapy, Prothena said.Prothena added that it will earn a $60 million clinical milestone payment upon first patient dosed in this study."Prasinezumab is the first anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early Parkinson's disease," Prothena said.The stock gained 11.01% to $12.50 in after-hours trading.Xeris' Investigational Drug Gets Fast Track Designation For Treating Acute Repetitive Seizures Xeris Pharmaceuticals Inc (NASDAQ: XERS) said the FDA granted fast track designation for the investigation of XP-0863 (diazepam non-aqueous injection) for the treatment of acute repetitive seizures.In after-hours trading, the stock was up 9.52% to $5.75.OncoCyte Rallies On Strong Adoption of its Lung Cancer Diagnostic Test Molecular diagnostic company OncoCyte Corp (NYSE: OCX) said testing volume of DetermaRx, its lung cancer diagnostic test launched in January, more than doubled quarter-over-quarter to 175 billable samples in the third quarter. The company also noted that it maintained a re-order rate of about 60% and onboard hospitals increased to 67.The stock added 7.38% to $1.60 in after-hours trading.Crispr Reports Positive Results For Cell Therapy In Early-stage Study In B-cell Malignancies Crispr Therapeutics AG (NASDAQ: CRSP) announced positive top-line results from its Phase 1 CARBON trial evaluating the safety and efficacy of CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies.View more earnings on IBB"While longer follow-up is required, these early data support the potential for CTX110 to become an effective off-the-shelf CAR-T therapy for patients with relapsed or refractory B-cell malignancies," said Joseph McGuirk, an investigator in the study.The stock was slipping 3% to $103.50 in pre-market trading.Actinium Announces NIH Grant For Study of its CD45-targeting Antibody Radio-conjugate Actinium Pharmaceuticals Inc (NYSE: ATNM) said the National Institutes of Health has awarded it a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center to study Iomab-ACT, Actinium's CD45-targeting antibody radio-conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK.The CD19 CAR-T has been previously studied by MSK in a Phase 2 trial with chemotherapy conditioning in patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma.In pre-market trading, the stock was up 6.67% to $11.68.Offerings Replimune Group Inc (NASDAQ: REPL) announced a proposed public offering of $125 million of shares of its common stock. All shares of common stock in the offering will be offered by the company.The stock was down 8.06% to $39 in after-hours trading.Aptinyx Inc (NASDAQ: APTX), which announced a positive mid-stage clinical readout late Tuesday, said it intends to offer and sell 12 million shares of its common stock in an underwritten public offering. All of the shares sold in the offering will be sold by the company.In after-hours trading, the stock shed 4.54% to $4.10.On The Radar Clinical Readouts Pfizer Inc. (NYSE: PFE) is scheduled to present at the ID Week 2020 full results of a pediatric Phase 2 proof-of-concept study of 20vPNC and detailed results from a Phase 2 proof-of-concept study of its potential first-in-class pentavalent meningococcal vaccine candidate.Earnings Abbott Laboratories (NYSE: ABT) (before the market open) Biogen Inc (NASDAQ: BIIB) (before the market open) Edwards Lifesciences Corp (NYSE: EW) (after the close)See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger * The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Athira Pharma Inc (NASDAQ: ATHA) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) - announced a deal to be bought by Endo International PLC (NASDAQ: ENDP) for $658 million or $88.50 per share in cash * Blueprint Medicines Corp (NASDAQ: BPMC) * CymaBay Therapeutics Inc (NASDAQ: CBAY) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX) * Immunomedics, Inc. (NASDAQ: IMMU) * Insmed Incorporated (NASDAQ: INSM) * Kymera Therapeutics Inc (NASDAQ: KYMR) * Larimar Therapeutics Inc (NASDAQ: LRMR) * Mirati Therapeutics Inc (NASDAQ: MRTX * Nevro Corp (NYSE: NVRO) * Pacific Biosciences of California Inc (NASDAQ: PACB) * Shockwave Medical Inc (NASDAQ: SWAV) * Tarsus Pharmaceuticals Inc (NASDAQ: TARS) (listed on Nasdaq Friday)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) * Dyne Therapeutics Inc (NASDAQ: DYN) * Gilead Sciences, Inc. (NASDAQ: GILD) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Opthea Limited (NASDAQ: OPT) (listed on Nasdaq Friday) * ProQR Therapeutics NV (NASDAQ: PRQR) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP)Stocks In Focus Aptinyx's NYX-783 Aces Midstage Study In Post-Traumatic Stress Disorder Aptinyx Inc (NASDAQ: APTX) announced positive results from the first Phase 2 study of its novel NMDA receptor modulator, NYX-783, in 153 patients with post-traumatic stress disorder.In the Phase 2 study, NYX-783 demonstrated statistically significant and clinically meaningful efficacy results and a favorable adverse event and tolerability profile, the company said.Based on these results, the company said it expects to initiate a pivotal study in 2021.The stock was jumping 92.35% to $7.04 premarket Tuesday.Cara Therapeutics Grants Vifor US License For Korsuva In Deal Valued Up To $440M Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma announced the signing of a license agreement for the commercialization of Korsuva injection for the treatment of chronic kidney disease associated with pruritus.Cara provided Vifor with the commercial rights for IV Korsuva in the non-Fresenius Medical Care dialysis clinics, with the agreement giving Cara a 60% share of the profit and Vifor 40%.Under the terms of the agreement, Cara will also receive an upfront payment of $100 million in cash and an equity investment of $50 million. In addition, Cara will be eligible to receive an additional equity investment upon U.S. regulatory approval of IV Korsuva, as well as milestone payments dependent on achieving commercial targets, which together could total up to $290 million.In premarket trading Tuesday, Cara shares were jumping 16.65% to $16.25.Centogene Raises FY20 Guidance Due On COVID-19 Testing, Recovery In Core Business Centogene NV (NASDAQ: CNTG) said it is increasing its full-year 2020 guidance from 60-65 million euros ($70.8 million to $75.6 million) to greater than 80 million euros.The company attributed the positive expectation to further developments in its commercial COVID-19 testing and the continued recovery of its core business since the second quarter.Separately, the company announced that CEO Arndt Rolfs is stepping down. Centogene is appointing Andrin Oswald as CEO effective Dec. 1. The stock was adding 4.77% to $12.75 premarket Tuesday.Related Link: The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference Merck Reports Positive Data For 2 Late-Stage Studies Of Pneumococcal Conjugate Vaccine Merck & Co., Inc. (NYSE: MRK) announced positive findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, its investigational 15-valent pneumococcal conjugate vaccine.Merck shares were up 0.47% to $79.04 premarket Tuesday.Cleveland BioLabs To Merge With Privately Held Cytocom In All-Stock Transaction Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced a definitive merger agreement to combine its business with Cytocom in an all-stock transaction.Cytocom shareholders will have a majority position in the newly combined entity. The shares will continue to be listed on the Nasdaq, and the initial board for the combined company will consist of four members selected by Cytocom and three members selected by Cleveland BioLabs. The boards of both companies have approved the combination.In premarket trading Tuesday, Cleveland shares were up 68.66% to $3.66.Inventiva Gets Fast Track Designation For Metabolic Disorder Drug Inventiva ADR Representing Ord Shs (NASDAQ: IVA) said the FDA has granted fast track designation to odiparcil, its clinical-stage drug candidate for the treatment of mucopolysaccharidoses type VI, a rare and progressive genetic disorder.In premarket trading Tuesday, the stock was up 5.59% to $14.35.Oric Pharma In-Licenses Genetic Cancer Drug ORIC Pharmaceuticals Inc (NASDAQ: ORIC) said it has entered into an exclusive license agreement with Voronoi to secure exclusive rights worldwide -- excluding China, Hong Kong, Macau and Taiwan -- for the development and commercialization of ORIC-114.The drug is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency against exon 20 insertion mutations.ORIC said it expects to initiate a global Phase 1/2 tumor-agnostic trial in genetically defined cancers during the second half of 2021.CytoDyn Says Data Monitoring Committee Recommends Continuation Of Registrational Late-Stage COVID-19 Study CytoDyn Inc (OTC: CYDY) said that following a first interim analysis, the Data Safety Monitoring Committee that reviewed data from its Phase 2b/3 registrational trial of leronlimab in patients with severe-to-critical COVID-19 recommended that the trial continue without modification to achieve the primary endpoint.The committee also requested another interim analysis when enrollment reaches the 75% level.Offerings BELLUS Health Inc (NASDAQ: BLU) said it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and LifeSci Capital, relating to the public offering of 15.56 million common shares.The shares are being sold at a public offering price of $2.25 per common share.The stock was down 0.43% at $2.31 premarket Tuesday.On The Radar PDUFA Dates Zosano Pharma Corp's (NASDAQ: ZSAN) NDA for its migraine drug Qtrypta has a PDUFA action date of Oct. 20. With the company disclosing in late September that it has received a discipline review letter, which raised two concerns about the clinical pharmacology section of the NDA, a decision Tuesday seems unlikely.Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs * The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.